| Project/Area Number |
20390036
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAZAKI Yuri 東京薬科大学, 薬学部, 助手 (70459725)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥15,340,000 (Direct Cost: ¥11,800,000、Indirect Cost: ¥3,540,000)
Fiscal Year 2010: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2009: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2008: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Keywords | 医薬品開発 / 抗がん剤 / 有機合成化学 / チューブリン作用薬 / プロドラッグ / ケミカルバイオロジー / 化学薬剤学 / 化学プローブ / 薬学 / 抗がん剤癌 / 血管内皮細胞障害 / チューブリン |
|---|
| Research Abstract |
Our efforts to develop novel m icrotubule depolymerization agents, which was focused on a natural diketopiperazine, phenylahistin, have succeeded in creating a highly potent anticancer drug candidate "Plinabulin" in Phase II clinical trials as a "vascular disrupting agent", which induces tumor-selective vascular collapse. SAR study from plinabulin has been conducted to develop more potent derivatives. A benzophenone derivative KPU-133 exhibited a 30-times higher cytotoxicity than plinabulin and would be promising candidates for further drug development. Moreover, to improve the low water-solubility of plinabulin(<0.1 mg/mL), a highly water-soluble prodrug(6 mg/mL in water) was developed to regenerate the parent drug by a unique skeletal transformation from monolactim to DKP. On the other hand, investigation of the tubulin-binding site using chemical probes indicated that plinabulin derivatives could interact in the interfacial region of α-and β-tubulin, which partially overlaps with the colchicine-binding site.
|
